Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00433355
Other study ID # 2006-0265
Secondary ID
Status Completed
Phase N/A
First received February 7, 2007
Last updated March 18, 2009
Start date January 2007
Est. completion date October 2008

Study information

Verified date March 2009
Source University of Mississippi Medical Center
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this study is to understand what causes a continuing fatigue for a long time with a number of symptoms occurring at the same time (Chronic Fatigue Syndrome-CFS). Epstein Barr Virus is among the group of viruses that have been associated with a continuing fatigue for a long time with a number of symptoms occurring at the same time, but the cause is still unknown.


Description:

Epstein-Barr virus (EBV) is the etiological agent for heterophile positive infectious mononucleosis (IM). It is also an oncogenic herpes virus associated with African Burkitt's lymphoma (BL),nasopharyngeal carcinoma (NPC) and AIDS-associated B-cell lymphomas. EBV is also among a group of viruses that have been associated with chronic fatigue syndrome (CFS), although the etiology of CFS still remains unknown.Findings may lead to hypothesize that EBV enzymes, such as the dUTPase, have the capacity to induce immune dysregulation of the T-cell and NK cell responses and that this immune dysregulation produces immunopathology that results in the symptoms that we call CFS.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date October 2008
Est. primary completion date August 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Healthy adults for controls.

- Adults with chronic fatigue syndrome.

Exclusion Criteria:

- Individuals with significant medical illness in reference to immunosuppressant drug.

Note: We recruit participants in the Mississippi area who could come in our site to provide blood draw.

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Locations

Country Name City State
United States University of Mississippi Medical Center Jackson Mississippi

Sponsors (2)

Lead Sponsor Collaborator
University of Mississippi Medical Center Ohio State University

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Recruiting NCT05454683 - Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome N/A
Completed NCT01686074 - Motor Control in Chronic Fatigue Syndrome and Fibromyalgia N/A
Completed NCT02075489 - Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans N/A
Completed NCT01651754 - Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome N/A
Completed NCT00540254 - Behavioral Insomnia Therapy With Chronic Fatigue Syndrome Phase 1/Phase 2
Active, not recruiting NCT00071162 - Genetics of Fibromyalgia N/A
Withdrawn NCT04870476 - Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome N/A
Completed NCT05730660 - Quercetin Phytosome® Chronic Fatigue Syndrome N/A
Recruiting NCT04542161 - Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Phase 2
Recruiting NCT03807973 - Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. Phase 1
Recruiting NCT05719493 - Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +) N/A
Recruiting NCT05967052 - Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation Phase 2
Terminated NCT01730495 - Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome Phase 2
Completed NCT01156909 - B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome Phase 2
Completed NCT01650636 - Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process N/A
Completed NCT01046370 - A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia N/A
Completed NCT00100412 - Hyporeactivity and Gulf War Illness N/A
Recruiting NCT06128967 - A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial Phase 3
Completed NCT02669212 - Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health N/A
Not yet recruiting NCT06011135 - Exploring Worry in CFS/ME